Colgate Palmolive CO

Colgate-Palmolive reported a 4.9% increase in net sales and a 2.4% rise in organic sales for Q2 2026, but GAAP EPS decreased by 5% while Base Business EPS grew 8%.

Colgate-Palmolive Company has announced a leadership transition in its legal department, with Betsy Fishbone appointed as Chief Legal Officer and Secretary, succeeding Jennifer M. Daniels.

Colgate-Palmolive Company announced the election of Christopher S. Boerner, Ph.D., CEO of Bristol Myers Squibb, to its Board of Directors, while Steven A. Cahillane will not seek re-election.

Colgate-Palmolive announced its fourth quarter and full year 2025 results, featuring sales growth but a significant GAAP EPS decline due to impairment charges.

Colgate-Palmolive Company has successfully issued €600 million in 3.250% Senior Notes due 2035, strengthening its long-term financing.

Colgate-Palmolive reported a 2.0% increase in net sales for Q3 2025, reaching $5.13 billion, while organic sales growth slowed to 0.4% and full-year organic sales guidance was lowered.

Colgate-Palmolive reported a 4.9% increase in net sales for Q2 2026, driven by volume and pricing, but net income attributable to the company decreased due to significant restructuring charges.

Colgate-Palmolive reports mixed Q3 2025 results with slight sales and EPS growth driven by pricing, while facing volume declines and margin pressure from higher costs.

Colgate-Palmolive reported a 1.0% increase in Q2 net sales and a 1.8% organic sales growth, but faced declining gross profit margins and operating profit, while announcing a new three-year productivity program and navigating ongoing legal and macroeconomic challenges.

Colgate-Palmolive's Q1 2025 net sales decreased by 3.1% year-over-year, impacted by foreign exchange rates, while the company navigates global economic challenges and invests in strategic growth areas.

Colgate-Palmolive's third-quarter 2024 results show a 2.4% increase in net sales and improved profitability, driven by volume growth and pricing actions, despite negative foreign exchange impacts.

Colgate-Palmolive's second quarter 2024 results show a significant increase in net sales and earnings per share, driven by volume growth and price increases.

Colgate-Palmolive reports 1.4% net sales growth in 2025, driven by pricing, but faces significant goodwill impairment and ongoing macroeconomic challenges.

Colgate-Palmolive's 2024 results show a 3.3% increase in net sales, driven by volume and pricing, with a positive outlook despite challenging global conditions.

Colgate-Palmolive's 10-K filing outlines the company's registered securities, including common stock and several series of medium-term and senior notes, along with details on corporate governance and risk factors.

Colgate-Palmolive COO, Americas, Shane Grant, reported a transaction involving the withholding of shares for tax purposes on June 16, 2026.

Brian Newman, a Director at Colgate-Palmolive, received an annual stock grant and stock options as part of the company's incentive compensation plan.

Kimberly A. Nelson, a Director at Colgate-Palmolive, received an annual stock grant and stock options as part of the company's incentive compensation plan.

Martina Hundmejean, a Director at Colgate-Palmolive, received stock grants and options on May 11, 2026, as part of the company's incentive compensation plan.

Colgate-Palmolive reports on director Lorrie M. Norrington's acquisition of common stock and stock options as part of the company's incentive compensation plan.

Colgate-Palmolive director Martin C. Harris received stock grants and options as part of the company's annual incentive compensation plan.

Colgate-Palmolive's latest proxy statement details 2025 performance, executive compensation, and a forward-looking 2030 strategy amidst challenging market conditions.

Colgate-Palmolive reminds stockholders to vote on proxy materials for the upcoming Annual Meeting of Stockholders to be held on May 9, 2025.

Colgate-Palmolive has announced its 2025 Annual Meeting of Stockholders, detailing proposals for voting including the election of directors, ratification of the company's accounting firm, executive compensation, and stockholder proposals regarding board independence and plastic packaging policies.

Colgate-Palmolive's 2025 proxy statement outlines key proposals for the annual meeting, including director elections, auditor ratification, and executive compensation advisory vote.

Colgate-Palmolive reminds stockholders to vote on proxy materials for the upcoming Annual Meeting on May 10, 2024, covering director elections, auditor ratification, executive compensation, and a stockholder proposal.

Colgate-Palmolive's 2024 Annual Meeting will be held virtually on May 10, 2024, with stockholders voting on director elections, auditor ratification, executive compensation, and a proposal for an independent Board Chairman.

Vanguard Capital Management has disclosed a beneficial ownership of 60,404,276 shares, representing 7.52% of Colgate-Palmolive's common stock, as of March 31, 2026.

The Vanguard Group, Inc. reported zero beneficial ownership of Colgate-Palmolive Co common stock following an internal realignment.

The Vanguard Group has filed an Amendment No. 12 to its Schedule 13G, disclosing a beneficial ownership of 10.05% of Colgate-Palmolive Co's common stock as of January 31, 2025.